Nephrotic syndrome in very elderly: Should we treat aggressively?

por Koratala, Abhilash, Tantravahi, Jogiraju
Publicado 2018

IgA nephropathy in African Americans: uncommon but possible

por Koratala, Abhilash, Clapp, William L, Esprit, Don H, Tantravahi, Jogiraju
Publicado 2018

Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression

por Quddus, M. Ruhul, Hansen, Katrine, Tantravahi, Umadevi, Sung, C. James
Publicado 2020

Evaluation of the Anticancer Properties of Geranyl Isovalerate, an Active Ingredient of Argyreia nervosa Extract in Colorectal Cancer Cells

por Rasool, Fayyaz, Sharma, Deepu, Anand, P. Shanmukha, Magani, SKJ, Tantravahi, Srinivasan
Publicado 2021

ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines

por Prasad, Anil, Khudaynazar, Nagina, Tantravahi, Ramana V., Gillum, Amanda M., Hoffman, Benjamin S.
Publicado 2016

An invasive weed-associated bacteria confers enhanced heat stress tolerance in wheat

por Dubey, Ankita, Kumar, Kundan, Srinivasan, Tantravahi, Kondreddy, Anil, Kumar, Koppolu Raja Rajesh
Publicado 2022

Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia

por Kim, Kibum, McMillin, Gwendolyn A., Bernard, Philip S., Tantravahi, Srinivas, Walker, Brandon S., Schmidt, Robert L.
Publicado 2019

P1020: SELINEXOR (SEL) PLUS RUXOLITINIB (RUX) IN JAK INHIBITOR (JAKI) TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS: UPDATED RESULTS FROM XPORT-MF-034

por Ali, Haris, Kishtagari, Ashwin, Maher, Keri, Mohan, Sanjay, Prchal, Josef, Wang, Xulong, Chamoun, Kamal, Tantravahi, Srinivas
Publicado 2023

An Integrated Human/Murine Transcriptome and Pathway Approach To Identify Prenatal Treatments For Down Syndrome

por Guedj, Faycal, Pennings, Jeroen LA, Massingham, Lauren J., Wick, Heather C., Siegel, Ashley E., Tantravahi, Umadevi, Bianchi, Diana W.
Publicado 2016

P1070: NAVITOCLAX MONOTHERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH JAK-2 INHIBITORS: SAFETY AND TOLERABILITY

por Pullarkat, V., Cruz-Chacon, A., Gangatharan, S., Melnyk, A., Palumbo, G. A., Bellini, M., Tantravahi, S. K., Qin, Q., Potluri, J., Vachhani, P.
Publicado 2022

P1005: A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAÏVE MYELOFIBROSIS

por Ali, H., Kishtagari, A., Maher, K., Mohan, S., Mazumder, A., Chamoun, K., Karasik, I., Sbar, E., Dugom, L., Tamir, S., Wang, X., Prchal, J., Tantravahi, S.
Publicado 2022

A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm

por Li, Peng, Venkatachalam, Shobi, Ospina Cordona, Daniela, Wilson, Lorena, Kovacsovics, Tibor, Moser, Karen A., Miles, Rodney R., Beck, David B., George, Tracy, Tantravahi, Srinivas K.
Publicado 2022

Survival Outcomes and Tumor IMP3 Expression in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma

por Tantravahi, Srinivas K., Albertson, Daniel, Agarwal, Archana M., Ravulapati, Sowmya, Poole, Austin, Patel, Shiven B., Hawatmeh, Jamil S., Straubhar, Alli M., Liu, Ting, Stenehjem, David D., Agarwal, Neeraj
Publicado 2015

Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2

por Gill, David M, Stenehjem, David D, Parikh, Kinjal, Merriman, Joseph, Sendilnathan, Arun, Agarwal, Archana M, Hahn, Andrew W, Gupta, Sumati, Tantravahi, Srinivas Kiran, Samlowski, Wolfram E, Agarwal, Neeraj
Publicado 2016

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms

por Patel, Ami B., Pomicter, Anthony D., Yan, Dongqing, Eiring, Anna M., Antelope, Orlando, Schumacher, Jonathan A., Kelley, Todd W., Tantravahi, Srinivas K., Kovacsovics, Tibor J., Shami, Paul J., O’Hare, Thomas, Deininger, Michael W.
Publicado 2020

RAPID CONVERSION OF CHRONIC MYELOID LEUKEMIA TO CHRONIC MYELOMONOCYTIC LEUKEMIA IN A PATIENT ON IMATINIB THERAPY

por Khorashad, Jamshid S., Tantravahi, Srinivas K., Yan, Dongqing, Mason, Clinton C., Qiao, Yi, Eiring, Anna M., Gligorich, Keith, Hein, Than, Pomicter, Anthony D., Reid, Alistair G., Kelley, Todd W., Marth, Gabor T., O'Hare, Thomas, Deininger, Michael W.
Publicado 2016

Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy

por Harrison, Claire N., Garcia, Jacqueline S., Somervaille, Tim C.P., Foran, James M., Verstovsek, Srdan, Jamieson, Catriona, Mesa, Ruben, Ritchie, Ellen K., Tantravahi, Srinivas K., Vachhani, Pankit, O'Connell, Casey L., Komrokji, Rami S., Harb, Jason, Hutti, Jessica E., Holes, Leanne, Masud, Abdullah A., Nuthalapati, Silpa, Potluri, Jalaja, Pemmaraju, Naveen
Publicado 2022

Combined STAT3 and BCR-ABL1 Inhibition Induces Synthetic Lethality in Therapy-Resistant Chronic Myeloid Leukemia

por Eiring, Anna M., Page, Brent D. G., Kraft, Ira L., Mason, Clinton C., Vellore, Nadeem A., Resetca, Diana, Zabriskie, Matthew S., Zhang, Tian Y., Khorashad, Jamshid S., Engar, Alexander J., Reynolds, Kimberly R., Anderson, David J., Senina, Anna, Pomicter, Anthony D., Arpin, Carolynn C., Ahmad, Shazia, Heaton, William L., Tantravahi, Srinivas K., Todic, Aleksandra, Moriggl, Richard, Wilson, Derek J., Baron, Riccardo, O'Hare, Thomas, Gunning, Patrick T., Deininger, Michael W.
Publicado 2014